Palatin to receive $12 million upfront, plus sales-based milestones of up to $159 million Palatin’s focus is solely on its development and clinical pipeline based on the melanocortin receptor system CRANBURY, N.J., Dec. 20, 2023 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American:…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.